Navidea biopharmaceuticals, inc. (NAVB)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue from contract with customer

38

338

-

-

-

-

-

-

-

-

-

Tc99m tilmanocept sales revenue

-

-

-

39

19

13

614

-

-

-

-

Lymphoseek sales revenue

-

-

-

-

-

-

-

0

0

-

-

Tc99m tilmanocept license revenue

-

-

-

1,795

1,133

300

-

-

-

-

-

Tc99m tilmanocept royalty revenue

-

-

-

0

0

-

-

-

-

-

-

Grant and other revenue

631

846

1,701

3,136

1,860

1,740

516

-

-

-

-

Lymphoseek milestone revenue

-

-

-

-

-

-

-

0

-

-

-

Grant and other revenue

-

-

-

-

-

-

-

78

597

-

-

Revenues, Total

657

1,169

1,810

4,971

3,013

2,054

1,130

78

597

617

-

Cost of revenue

6

96

3

-

-

-

-

-

-

-

-

Cost of goods sold

-

-

-

62

3

2

332

0

0

-

-

Gross profit

651

1,072

1,806

4,909

3,010

2,051

797

78

597

-

-

Operating expenses:
Research and development

-

-

-

-

-

-

23,710

-

-

-

-

Selling, general and administrative

-

-

-

-

-

-

15,525

-

-

-

-

Research and development

5,338

4,221

4,513

7,138

10,562

15,116

-

16,890

15,154

8,941

4,379

Selling, general and administrative

6,275

7,698

11,169

7,920

10,888

9,525

-

11,177

9,547

4,353

3,028

Total operating expenses

11,613

11,920

15,683

15,058

21,450

24,642

39,236

28,068

24,702

13,294

7,408

Loss from operations

-10,962

-10,847

-13,877

-10,148

-18,440

-22,591

-38,438

-27,989

-24,104

-12,676

-7,408

Other income (expense):
Interest income, net

-

-

168

-4

-1,269

-3,363

-2,759

-

-

-

-

Interest (expense) income, net

25

-30

-

-

-

-

-

25

25

8

18

Interest expense

-

-

-

-

-

-

-

1,166

13

554

1,533

Equity in loss of R-NAV, LLC

-

-

-

-15

-305

-523

-

0

-

-

-

Loss on disposal of investment in R-NAV, LLC

-

-

-

-39

0

0

-

-

-

-

-

Change in fair value of financial instruments

-

-

153

2,858

-614

-1,342

-112

32

-952

-

-

Change in fair value of financial instruments

-

-

153

2,858

-614

-1,342

-

32

-952

-

-

Loss on extinguishment of debt

-

-5,291

-4,201

0

-2,440

-2,610

-1,372

0

0

-41,717

-16,240

Change in derivative liabilities

-

-

-

-

-

-

-

-

-

-1,336

-18,132

Other, net

-7

1

-33

-27

26

72

-16

-58

-3

32

-3

Total other income (expense), net

17

-5,321

-3,912

2,770

-4,603

-7,767

-4,261

-

-

-

-

Loss before income taxes

-10,944

-16,168

-17,789

-7,377

-23,044

-30,358

-42,699

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-25,047

-56,243

-43,298

Provision for income taxes

0

-9

-4,062

0

0

-

-

-

-7,880

2,134

-1,255

Net loss from continuing operations

-10,945

-16,158

-13,727

-7,377

-23,044

-

-42,699

-

-

-

-

Discontinued operations, net of tax effect:
Loss from discontinued operations, net of tax effect

-2

1

-490

-6,931

-4,518

-5,367

-

-

-

-

-

Impairment loss

-

-

-

-

-

-

-

-

-

-

1,131

Loss from discontinued operations

-

-

-

-

-

-

-

-

3,329

4,144

3,568

Gain on sale of discontinued operations, net of tax effect

-

43

89,163

0

0

-

-

-

19,450

0

-

Net loss

-10,948

-16,114

74,945

-14,309

-27,563

-35,726

-42,699

-

-

-

-

Income (loss) attributable to noncontrolling interest

-0

-0

-0

-0

-0

0

-

-

-

-

-

Net income (loss) attributable to common stockholders

-

-

-

-

-

-

-

-

5,612

-49,964

-39,605

Deemed dividend on beneficial conversion feature of MT Preferred Stock

-

-

-

0

46

0

-

-

-

-

-

Total other expense, net

-

-

-

-

-

-

-

-1,167

-943

-43,567

-35,890

Net loss

-

-

-

-

-

-

-

-29,157

-17,167

-54,109

-42,043

Preferred stock dividends

-

-

-

-

-

-

-

43

100

8,206

240

Net loss attributable to common stockholders

-10,948

-16,113

74,946

-14,308

-27,608

-35,726

-42,699

-29,200

5,512

-58,171

-39,845

Continuing operations (in dollars per share)

-

-

-0.08

-0.05

-0.15

-

-

-

-

-

-

Discontinued operations (in dollars per share)

-

-

0.55

-0.04

-0.03

-

-

-

-

-

-

Attributable to common stockholders (in dollars per share)

-

-

0.47

-0.09

-0.18

-

-

-

-

-

-

Weighted average shares outstanding (in shares)

-

-

161,592

155,422

151,180

-

-

-

-

-

-

Continuing operations (in dollars per share)

-

-

-0.08

-0.05

-0.15

-

-

-

-

-

-

Discontinued operations (in dollars per share)

-

-

0.53

-0.04

-0.03

-

-

-

-

-

-

Attributable to common stockholders (in dollars per share)

-

-

0.45

-0.09

-0.18

-

-

-

-

-

-

Weighted average shares outstanding (diluted) (in shares)

-

-

166,016

155,422

151,180

-

-

-

-

-

-

Loss per common share (basic and diluted):
Continuing operations (in dollars per share)

-0.76

-1.90

-

-

-

-0.20

-0.35

-

-0.17

-0.77

-0.57

Discontinued operations (in dollars per share)

-

0.01

-

-

-

-0.04

-

-

0.23

0.05

0.03

Attributable to common stockholders (in dollars per share)

-0.76

-1.89

-

-

-

-0.24

-0.35

-0.29

0.06

-0.72

-0.54

Weighted average shares outstanding (in shares)

14,393

8,526

-

-

-

148,748

121,808

99,059

90,509

80,726

-

Basic and diluted

-

-

-

-

-

-

-

-

-

-

73,771

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-39,605

Unrealized loss on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-1

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-39,607

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

240

Comprehensive income (loss) attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-39,847

Royalty [Member]
Revenue from contract with customer

16

15

9

-

-

-

-

-

-

-

-

License [Member]
Revenue from contract with customer

9

307

100

-

-

-

-

-

-

-

-